Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 8/20 | 0.61 |
| ▸ | NPY4R | P50391 | 8/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.61 |
| ▸ | NPY1R | P25929 | 6/20 | 0.60 |
| ▸ | TFPI | P10646 | 6/20 | 0.58 |
| ▸ | KDM1A | O60341 | 2/20 | 0.57 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.56 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.56 |
| ▸ | CALCR | P30988 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12038577 | 0.94 | NPY2R (0.60) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL25544142 | 0.88 | NPY2R (0.59) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL12038559 | 0.87 | NPY2R (0.59) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29263405 | 0.87 | NPY2R (0.62) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL30432199 | 0.86 | NPY2R (0.67) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL21462831 | 0.86 | NPY2R (0.62) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL21462828 | 0.86 | NPY2R (0.62) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL12038635 | 0.86 | KDM1A (0.55) | TFPIKDM1ACALCR | |
| SCHEMBL30436596 | 0.85 | MAPK8 (0.65) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29903341 | 0.85 | NPY2R (0.66) | NPY2RNPY4RNPY5RNPY1RTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783578-B2 | Immunosuppression modulating compounds | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-10-10 | — | — | US | disclosed |
| US-20150087581-A1 | Immunosuppression Modulating Compounds | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
| US-8907053-B2 | Immunosuppression modulating compounds | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-12-09 | — | — | US | disclosed |
| US-20110318373-A1 | IMMUNOSUPPRESSION MODULATING COMPOUNDS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110318373-A1 | IMMUNOSUPPRESSION MODULATING COMPOUNDS | CD274, PDCD1, PDCD1LG2 | NPY2R 3711/4885NPY4R 4103/4885NPY5R 3409/4885 |
| US-20150087581-A1 | Immunosuppression Modulating Compounds | CD274, PDCD1, PDCD1LG2 | NPY2R 3796/4885NPY4R 4170/4885NPY5R 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.